Antitumor effects of epidrug/IFNα combination driven by modulated gene signatures in both colorectal cancer and dendritic cells

Alessandra Fragale, Giulia Romagnoli, Valerio Licursi, Maria Buoncervello, Giorgia Del Vecchio, Caterina Giuliani, Stefania Parlato, Celeste Leone, Marta De Angelis, Irene Canini, Elena Toschi, Filippo Belardelli, Rodolfo Negri, Imerio Capone, Carlo Presutti, Lucia Gabriele

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Colorectal cancer results from the progressive accumulation of genetic and epigenetic alterations. IFN signaling defects play an important role in the carcinogenesis process, in which the inability of IFN transcription regulatory factors (IRF) to access regulatory sequences in IFN-stimulated genes (ISG) in tumors and in immune cells may be pivotal. We reported that low-dose combination of two FDA-approved epidrugs, azacytidine (A) and romidepsin (R), with IFNα2 (ARI) hampers the aggressiveness of both colorectal cancer metastatic and stem cells in vivo and triggers immunogenic cell death signals that stimulate dendritic cell (DC) function. Here, we investigated the molecular signals induced by ARI treatment and found that this drug combination increased the accessibility to regulatory sequences of ISGs and IRFs that were epigenetically silenced in both colorectal cancer cells and DCs. Likewise, specific ARI-induced histone methylation and acetylation changes marked epigenetically affected ISG promoters in both metastatic cancer cells and DCs. Analysis by ChIPseq confirmed such ARI-induced epigenetically regulated IFN signature. The activation of this signal endowed DCs with a marked migratory capability. Our results establish a direct correlation between reexpression of silenced ISGs by epigenetic control and ARI anticancer activity and provide new knowledge for the development of innovative combined therapeutic strategies for colorectal cancer. Cancer Immunol Res; 5(7); 604-16.

Original languageEnglish
Pages (from-to)604-616
Number of pages13
JournalCancer immunology research
Volume5
Issue number7
DOIs
Publication statusPublished - Jul 1 2017

Fingerprint

Dendritic Cells
Colorectal Neoplasms
Epigenomics
Genes
Azacitidine
Neoplasms
Neoplastic Stem Cells
Drug Combinations
Acetylation
Histones
Methylation
Carcinogenesis
Cell Death
Transcription Factors
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Cite this

Antitumor effects of epidrug/IFNα combination driven by modulated gene signatures in both colorectal cancer and dendritic cells. / Fragale, Alessandra; Romagnoli, Giulia; Licursi, Valerio; Buoncervello, Maria; Del Vecchio, Giorgia; Giuliani, Caterina; Parlato, Stefania; Leone, Celeste; De Angelis, Marta; Canini, Irene; Toschi, Elena; Belardelli, Filippo; Negri, Rodolfo; Capone, Imerio; Presutti, Carlo; Gabriele, Lucia.

In: Cancer immunology research, Vol. 5, No. 7, 01.07.2017, p. 604-616.

Research output: Contribution to journalArticle

Fragale, Alessandra ; Romagnoli, Giulia ; Licursi, Valerio ; Buoncervello, Maria ; Del Vecchio, Giorgia ; Giuliani, Caterina ; Parlato, Stefania ; Leone, Celeste ; De Angelis, Marta ; Canini, Irene ; Toschi, Elena ; Belardelli, Filippo ; Negri, Rodolfo ; Capone, Imerio ; Presutti, Carlo ; Gabriele, Lucia. / Antitumor effects of epidrug/IFNα combination driven by modulated gene signatures in both colorectal cancer and dendritic cells. In: Cancer immunology research. 2017 ; Vol. 5, No. 7. pp. 604-616.
@article{adebacbddd0f4f55bdbd7d0305e2eb5d,
title = "Antitumor effects of epidrug/IFNα combination driven by modulated gene signatures in both colorectal cancer and dendritic cells",
abstract = "Colorectal cancer results from the progressive accumulation of genetic and epigenetic alterations. IFN signaling defects play an important role in the carcinogenesis process, in which the inability of IFN transcription regulatory factors (IRF) to access regulatory sequences in IFN-stimulated genes (ISG) in tumors and in immune cells may be pivotal. We reported that low-dose combination of two FDA-approved epidrugs, azacytidine (A) and romidepsin (R), with IFNα2 (ARI) hampers the aggressiveness of both colorectal cancer metastatic and stem cells in vivo and triggers immunogenic cell death signals that stimulate dendritic cell (DC) function. Here, we investigated the molecular signals induced by ARI treatment and found that this drug combination increased the accessibility to regulatory sequences of ISGs and IRFs that were epigenetically silenced in both colorectal cancer cells and DCs. Likewise, specific ARI-induced histone methylation and acetylation changes marked epigenetically affected ISG promoters in both metastatic cancer cells and DCs. Analysis by ChIPseq confirmed such ARI-induced epigenetically regulated IFN signature. The activation of this signal endowed DCs with a marked migratory capability. Our results establish a direct correlation between reexpression of silenced ISGs by epigenetic control and ARI anticancer activity and provide new knowledge for the development of innovative combined therapeutic strategies for colorectal cancer. Cancer Immunol Res; 5(7); 604-16.",
author = "Alessandra Fragale and Giulia Romagnoli and Valerio Licursi and Maria Buoncervello and {Del Vecchio}, Giorgia and Caterina Giuliani and Stefania Parlato and Celeste Leone and {De Angelis}, Marta and Irene Canini and Elena Toschi and Filippo Belardelli and Rodolfo Negri and Imerio Capone and Carlo Presutti and Lucia Gabriele",
year = "2017",
month = "7",
day = "1",
doi = "10.1158/2326-6066.CIR-17-0080",
language = "English",
volume = "5",
pages = "604--616",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Antitumor effects of epidrug/IFNα combination driven by modulated gene signatures in both colorectal cancer and dendritic cells

AU - Fragale, Alessandra

AU - Romagnoli, Giulia

AU - Licursi, Valerio

AU - Buoncervello, Maria

AU - Del Vecchio, Giorgia

AU - Giuliani, Caterina

AU - Parlato, Stefania

AU - Leone, Celeste

AU - De Angelis, Marta

AU - Canini, Irene

AU - Toschi, Elena

AU - Belardelli, Filippo

AU - Negri, Rodolfo

AU - Capone, Imerio

AU - Presutti, Carlo

AU - Gabriele, Lucia

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Colorectal cancer results from the progressive accumulation of genetic and epigenetic alterations. IFN signaling defects play an important role in the carcinogenesis process, in which the inability of IFN transcription regulatory factors (IRF) to access regulatory sequences in IFN-stimulated genes (ISG) in tumors and in immune cells may be pivotal. We reported that low-dose combination of two FDA-approved epidrugs, azacytidine (A) and romidepsin (R), with IFNα2 (ARI) hampers the aggressiveness of both colorectal cancer metastatic and stem cells in vivo and triggers immunogenic cell death signals that stimulate dendritic cell (DC) function. Here, we investigated the molecular signals induced by ARI treatment and found that this drug combination increased the accessibility to regulatory sequences of ISGs and IRFs that were epigenetically silenced in both colorectal cancer cells and DCs. Likewise, specific ARI-induced histone methylation and acetylation changes marked epigenetically affected ISG promoters in both metastatic cancer cells and DCs. Analysis by ChIPseq confirmed such ARI-induced epigenetically regulated IFN signature. The activation of this signal endowed DCs with a marked migratory capability. Our results establish a direct correlation between reexpression of silenced ISGs by epigenetic control and ARI anticancer activity and provide new knowledge for the development of innovative combined therapeutic strategies for colorectal cancer. Cancer Immunol Res; 5(7); 604-16.

AB - Colorectal cancer results from the progressive accumulation of genetic and epigenetic alterations. IFN signaling defects play an important role in the carcinogenesis process, in which the inability of IFN transcription regulatory factors (IRF) to access regulatory sequences in IFN-stimulated genes (ISG) in tumors and in immune cells may be pivotal. We reported that low-dose combination of two FDA-approved epidrugs, azacytidine (A) and romidepsin (R), with IFNα2 (ARI) hampers the aggressiveness of both colorectal cancer metastatic and stem cells in vivo and triggers immunogenic cell death signals that stimulate dendritic cell (DC) function. Here, we investigated the molecular signals induced by ARI treatment and found that this drug combination increased the accessibility to regulatory sequences of ISGs and IRFs that were epigenetically silenced in both colorectal cancer cells and DCs. Likewise, specific ARI-induced histone methylation and acetylation changes marked epigenetically affected ISG promoters in both metastatic cancer cells and DCs. Analysis by ChIPseq confirmed such ARI-induced epigenetically regulated IFN signature. The activation of this signal endowed DCs with a marked migratory capability. Our results establish a direct correlation between reexpression of silenced ISGs by epigenetic control and ARI anticancer activity and provide new knowledge for the development of innovative combined therapeutic strategies for colorectal cancer. Cancer Immunol Res; 5(7); 604-16.

UR - http://www.scopus.com/inward/record.url?scp=85022069828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022069828&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-17-0080

DO - 10.1158/2326-6066.CIR-17-0080

M3 - Article

AN - SCOPUS:85022069828

VL - 5

SP - 604

EP - 616

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 7

ER -